7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A relativity concept in mesenchymal stromal cell manufacturing.

      1 , 2 , 3

      Cytotherapy

      Elsevier BV

      MSCs, cellular therapy, clinical trial, manufacturing

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mesenchymal stromal cells (MSCs) are being experimentally tested in several biological systems and clinical settings with the aim of verifying possible therapeutic effects for a variety of indications. MSCs are also known to be heterogeneous populations, with phenotypic and functional features that depend heavily on the individual donor, the harvest site, and the culture conditions. In the context of this multidimensional complexity, a recurrent question is whether it is feasible to produce MSC batches as "standard" therapeutics, possibly within scalable manufacturing systems. Here, we provide a short overview of the literature on different culture methods for MSCs, including those employing innovative technologies, and of some typically assessed functional features (e.g., growth, senescence, genomic stability, clonogenicity, etc.). We then offer our perspective of a roadmap on how to identify and refine manufacturing systems for MSCs intended for specific clinical indications. We submit that the vision of producing MSCs according to a unique standard, although commercially attractive, cannot yet be scientifically substantiated. Instead, efforts should be concentrated on standardizing methods for characterization of MSCs generated by different groups, possibly covering a vast gamut of functionalities. Such assessments, combined with hypotheses on the therapeutic mode of action and associated clinical data, should ultimately allow definition of in-process controls and measurable release criteria for MSC manufacturing. These will have to be validated as predictive of potency in suitable pre-clinical models and of therapeutic efficacy in patients.

          Related collections

          Author and article information

          Journal
          Cytotherapy
          Cytotherapy
          Elsevier BV
          1477-2566
          1465-3249
          May 2016
          : 18
          : 5
          Affiliations
          [1 ] Department of Biomedicine, University Hospital Basel, Basel, Switzerland. Electronic address: ivan.martin@usb.ch.
          [2 ] Merln Institute for Technology-inspired Regenerative Medicine, Maastricht University, Maastricht, The Netherlands.
          [3 ] UMR5273 STROMALab Centre National de la Recherche Scientifique (CNRS)/Établissement Français du Sang (EFS)/Universite Paul Sabatier (UPS), Institut National de la Sante et de la Recherche Médicale (INSERM), U1031, Toulouse, France.
          Article
          S1465-3249(16)00042-6
          10.1016/j.jcyt.2016.02.004
          27059199

          manufacturing, MSCs, cellular therapy, clinical trial

          Comments

          Comment on this article